Price
No data yet.
Social Signal Score
Revenue
$3.76B+22.89%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Scott Andrew Smith
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 30,000
- Beta
- 0.88
- Country
- US
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 1.09
Financials
Revenue
$3.76B+22.9%Net Income
$-118.80MEBITDA
$653.30M+146.5%Free Cash Flow
$329.00M-69.6%EPS (diluted)
$-0.10Shares Outstanding (diluted)
1.16B+122.2%Operating Expenses
$1.38BCash & Debt
$1.51BReturn of Capital
$289.80MRevenue by Segment (annual)
$14.25BDividend per Share
$0.12Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $14.30B | $-3.51B | $-3.00 |
| 2024 | $14.74B | $-634.20M | $-0.53 |
| 2023 | $15.43B | $54.70M | $0.05 |
| 2022 | $16.26B | $2.08B | $1.71 |
| 2021 | $17.89B | $-1.27B | $-1.05 |
| 2020 | $11.95B | $-669.90M | $-1.11 |
| 2019 | $11.50B | $16.80M | $0.03 |
| 2018 | $11.43B | $352.50M | $0.69 |
| 2017 | $11.91B | $696.00M | $1.30 |
| 2016 | $11.08B | $480.00M | $0.94 |
| 2015 | $9.43B | $847.60M | $1.80 |
| 2014 | $7.72B | $929.40M | $2.49 |
| 2013 | $6.91B | $623.70M | $1.63 |
| 2012 | $6.80B | $640.85M | $1.54 |
Valuation
VTRShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100-16.67%Social Signal Score
Mentions (2)
- News (Marketaux)economictimes.indiatimes.com·1d ago·Neutral
Sun Pharma gets ratings boost from Moody's, S&P over USD 11.75-bn Organon & Co acquisition bid (BBB-/Stable/--) and Viatris <e[+99 characters]
View source ↗ - Newsproactiveinvestors.co.uk·12d ago·Positive
Cavendish reiterates 'buy' rating on Shield Therapeutics after US deal with Viatris Cavendish has reiterated its buy rating on Shield Therapeutics PLC (AIM:STX, OTCQB:SHIEF) following the pharmaceutical company's agreement to take full commercial control of its main United States (US) product from Viatris. The broker kept its target price at 23 pence, implying potential upside of 318% from current share price of about 5.5 pence.
View source ↗
Earnings
Thu, Nov 5(in 8 weeks)
Consensus estimate $0.67 per share
Typical surprise +7.9% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$0.69 vs $0.60beat
- Thu, May 7$0.59 vs $0.50beat
- Thu, Feb 26$0.57 vs $0.53beat
- Thu, Nov 6$0.67 vs $0.62beat
- Thu, Aug 7$0.62 vs $0.56beat
- Thu, May 8$0.50 vs $0.49beat
Estimates and results for VTRS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by VTRS officers and directors.
- Bought
- $5k
- Sold
- $1.1m
2 trades
2 trades
- Campbell Paulsold
- Campbell Paulsold
- Simmons David Sbought
- Simmons David Sbought
96 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.